Prevention of Chemotherapy-Induced Nausea and Vomiting by Olanzapine in Japanese Female Patients with Early Breast Cancer who had Poor Control with the Standard Antiemetic Regimen
نویسندگان
چکیده
Aim: To evaluate the antiemetic efficacy and safety of olanzapine in Japanese women with nausea and/or vomiting refractory to the standard antiemetic regimen. Methods: We retrospectively reviewed the medical records of consecutive female patients with early breast cancer who underwent highly emetogenic chemotherapy at our hospital from January 2009 to March 2013. Patients with grade 2 or 3 nausea and/or vomiting despite receiving standard antiemetics (5-hydroxytryptamine3 receptor antagonists and dexamethasone 20 mg on day 1, and 4 mg dexamethasone on days 2 and 3) in the first chemotherapy cycle received an additional 2.5–10 mg olanzapine from days 1 to 3 in the subsequent cycles. We assessed patient characteristics, olanzapine dose, nausea and vomiting grades before and after adding olanzapine, and adverse effects. Results: We reviewed 20 patients with poor control in the first chemotherapy cycle, despite receiving standard antiemetics, who received olanzapine from the second cycle. Nausea and vomiting improved in 75% and 70% of cases, respectively, despite poor control during the first cycle, while an additional 10% of cases achieved a complete response (no emesis, no rescue) in the second cycle. No grade 3/4 adverse events were noted, but 50% and 30% of subjects complained of grade 1/2 drowsiness and dizziness, respectively, prompting a reduction in the olanzapine dose. Efficacy was retained at the lower dose. Conclusion: Olanzapine has excellent antiemetic efficacy in Japanese women with chemotherapy-induced nausea and vomiting refractory to standard antiemetics. The recommended dose of olanzapine for Japanese women appears to be lower than for Caucasians.
منابع مشابه
The Effect of Group Behavioral Activation Therapy on Chemotherapy - induced Nausea and Vomiting among Women with Breast Cancer
Background and Aim: Nausea and vomiting are one of the most common and worst side effects of chemotherapy in breast cancer patient and and despite the advances in medical science, Chemotherapy Induced Nausea and Vomiting is still a challenge to control.The aim of this study was to investigate the effect of group behavioral activation therapy on Chemotherapy Induced Nausea and Vomiting among wom...
متن کاملEfficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
OBJECTIVE Olanzapine is proved to be effective for chemotherapy induced nausea and vomiting (CINV). But its efficacy in combination with standard antiemetic therapy is unknown. The purpose of this study is to prove the preventive effect of olanzapine for the prevention of CINV caused by highly emetogenic chemotherapy when used with standard antiemetic therapy. METHOD Gynecologic cancer patien...
متن کاملThe Affect of Ginger on the Severity of Nausea and Vomiting induced by Chemotherapy in Cancer' Patient Referred to Razi Hospital in Rasht 2007-2008
Introduction: nausea and vomiting caused by chemotherapy is the most important ‎complication and discomfort for cancer patients. Nausea and vomiting causes physiologic and ‎electrolyte disorders, Immunity system changes, Nutrition disorders and rupture of esophagus ‎and effect in the quality of life and continuing of patient's treatment. Ginger is one vegetable ‎and effective dr...
متن کاملCost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
PURPOSE Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving chemotherapy. The objective of this study was to define, from the UK payer perspective, the cost-effectiveness of an antiemetic regimen using aprepitant, a selective neurokinin-1 receptor antagonist, for patients receiving chemotherapy for breast cancer. METHODS A decision-an...
متن کاملTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30-50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthrough CINV. International guidelines recommend the treatment of breakthrough CINV with an agent from ...
متن کامل